Kadmon (KDMN) Stock Price Up -1.6%
Shares of Kadmon Holdings Inc (NYSE:KDMN) rose 1.6% during trading on Thursday . The company traded as high as $5.20 and last traded at $5.03. Approximately 285,234 shares changed hands during trading, a decline of 77% from the average daily volume of 1,230,544 shares. The stock had previously closed at $5.11.
KDMN has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kadmon in a research report on Friday, November 17th. Zacks Investment Research raised Kadmon from a “sell” rating to a “hold” rating in a research report on Tuesday, November 21st. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $8.65.
Kadmon (NYSE:KDMN) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.04). The firm had revenue of $2.28 million during the quarter, compared to analyst estimates of $5.69 million. The firm’s revenue for the quarter was down 60.0% on a year-over-year basis. During the same period in the previous year, the business posted ($4.24) earnings per share. research analysts anticipate that Kadmon Holdings Inc will post -1.62 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Kadmon (KDMN) Stock Price Up -1.6%” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/02/10/kadmon-kdmn-stock-price-up-1-6.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.